A patent review of the ubiquitin ligase system: 2015–2018

ABSTRACT Introduction: Ubiquitin-proteasome system (UPS) has been validated as a novel anticancer drug target in the past 20 years. The UPS contains two distinct steps: ubiquitination of a substrate protein by ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3), and substrate degradation by the 26S proteasome complex. The E3 enzyme is the central player in the ubiquitination step and has a wide range of specific substrates in cancer cells, offering great opportunities for discovery and development of selective drugs. Areas covered: This review summarizes the recent advances in small molecule inhibitors of E1s, E2s, and E3s, with a focus on the latest patents (from 2015 to 2018) of E3 inhibitors and modulators. Expert opinion: One strategy to overcome limitations of current 20S proteasome inhibitors is to discover inhibitors of the upstream key components of the UPS, such as E3 enzymes. E3s play important roles in cancer development and determine the specificity of substrate ubiquitination, offering novel target opportunities. E3 modulators could be developed by rational design, natural compound or library screening, old drug repurposes, and application of other novel technologies. Further understanding of mechanisms of E3–substrate interaction will be essential for discovering and developing next-generation E3 inhibitors as effective anticancer drugs.

• Publication year

  2018

• Venue

  Expert Opinion on Therapeutic Patents

• Publication date

  2018-11-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/13543776.2018.1549229PMID 30449221PMCID PMC6398165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Protein–Protein Interaction Network of Litopenaeus vannamei Haemocytes

  2019cited by this paper
• Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

  2019cited by this paper
• Emerging drug development technologies targeting ubiquitination for cancer therapeutics

  2019cited by this paper
• Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity

  2018cited by this paper
• A novel NAE/UAE dual inhibitor LP0040 blocks neddylation and ubiquitination leading to growth inhibition and apoptosis of cancer cells.

  2018cited by this paper
• A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

  2018cited by this paper
• Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

  2018cited by this paper
• RNA interference-based therapy and its delivery systems

  2018cited by this paper
• Indole‐3‐carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4‐1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells

  2017cited by this paper
• Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)

  2017influential reference
• Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by Fragment Screening

  2017cited by this paper
• MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

  2017cited by this paper
• A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53

  2017cited by this paper
• Drugging the undruggables: exploring the ubiquitin system for drug development

  2016cited by this paper
• System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes.

  2016influential reference
• Small molecule therapeutics targeting F-box proteins in cancer.

  2016cited by this paper
• Recent advances in SCF ubiquitin ligase complex: Clinical implications.

  2016cited by this paper
• RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.

  2016cited by this paper
• Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors.

  2016cited by this paper
• Discovery of a novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine Scaffold by Structure-Based Virtual Screening.

  2016cited by this paper
• MLN4924 therapy as a novel approach in cancer treatment modalities

  2016influential reference
• A Chemical Inhibitor of the Skp2/p300 Interaction that Promotes p53-Mediated Apoptosis.

  2016cited by this paper
• E2 enzymes: more than just middle men

  2016influential reference
• Ubiquitin modifications

  2016cited by this paper
• Ubc13: the Lys63 ubiquitin chain building machine

  2016cited by this paper
• HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

  2015influential reference
• Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation

  2015cited by this paper
• Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme.

  2015cited by this paper
• Small-molecule MDM2-p53 inhibitors: recent advances.

  2015cited by this paper
• An inhibitor of ubiquitin conjugation and aggresome formation† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc01351h Click here for additional data file.

  2015cited by this paper
• Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

  2015cited by this paper
• Phthalimide conjugation as a strategy for in vivo target protein degradation

  2015cited by this paper
• 255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models

  2014cited by this paper
• Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities

  2014cited by this paper
• Applied techniques for mining natural proteasome inhibitors.

  2014cited by this paper
• Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.

  2014cited by this paper
• RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination.

  2014influential reference
• The role of ubiquitin modification in the regulation of p53.

  2014cited by this paper
• A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

  2014cited by this paper
• The role of ginsenosides in inhibiting ubiquitin activating enzyme (E1) activity

  2014cited by this paper
• Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme.

  2014cited by this paper
• Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects.

  2014cited by this paper
• Peptide and small molecule inhibitors of HECT-type ubiquitin ligases

  2014influential reference
• Development of inhibitors in the ubiquitination cascade

  2013cited by this paper
• Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

  2013influential reference
• Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation.

  2013cited by this paper
• Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via Unfolded Protein Response Signaling

  2013cited by this paper
• Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells.

  2013cited by this paper
• High-Throughput Screening AlphaScreen Assay for Identification of Small-Molecule Inhibitors of Ubiquitin E3 Ligase SCFSkp2-Cks1

  2013cited by this paper
• E6AP/UBE3A Ubiquitin Ligase Harbors Two E2∼ubiquitin Binding Sites*

  2013cited by this paper
• Genistein down-regulates miR-223 expression in pancreatic cancer cells.

  2013cited by this paper
• Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.

  2013cited by this paper
• Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors.

  2013cited by this paper
• Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

  2013cited by this paper
• E2 enzyme inhibition by stabilization of a low affinity interface with ubiquitin

  2013cited by this paper
• The p27–Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells

  2013cited by this paper
• Specific small molecule inhibitors of Skp2-mediated p27 degradation.

  2012cited by this paper
• Identification and Mechanistic Studies of a Novel Ubiquitin E1 Inhibitor

  2012cited by this paper
• Largazole and Its Derivatives Selectively Inhibit Ubiquitin Activating Enzyme (E1)

  2012cited by this paper
• Small molecules that bind the Mdm2 RING stabilize and activate p53.

  2012cited by this paper
• Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells.

  2012cited by this paper
• The ubiquitin code.

  2012cited by this paper
• Manadosterols A and B, sulfonated sterol dimers inhibiting the Ubc13-Uev1A interaction, isolated from the marine sponge Lissodendryx fibrosa.

  2012cited by this paper
• Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening.

  2012cited by this paper
• Cks1 Is Required for Tumor Cell Proliferation but Not Sufficient to Induce Hematopoietic Malignancies

  2012cited by this paper
• MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

  2012cited by this paper
• Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase β-TrCP1

  2012cited by this paper
• Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma

  2012cited by this paper
• Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis

  2012cited by this paper
• Targeting the Oncogenic E3 Ligase Skp2 in Prostate and Breast Cancer Cells with a Novel Energy Restriction-Mimetic Agent

  2012cited by this paper
• Hyrtioreticulins A-E, indole alkaloids inhibiting the ubiquitin-activating enzyme, from the marine sponge Hyrtios reticulatus.

  2012cited by this paper
• NEDD8 pathways in cancer, Sine Quibus Non.

  2011cited by this paper
• RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis

  2011cited by this paper
• 1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein.

  2011cited by this paper
• An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

  2011cited by this paper
• Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues

  2011cited by this paper
• miR-27a regulation of SCFFbw7 in cell division control and cancer

  2011cited by this paper
• A comparison between Skp2 and FOXO1 for their cytoplasmic localization by Akt1

  2010cited by this paper
• The Tumour Suppressor C / EBP delta Inhibits FBXW 7 Expression and Promotes Mammary Tumour Metastasis

  2010cited by this paper
• An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase

  2010cited by this paper
• SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.

  2010cited by this paper
• Protein-Protein Interaction Antagonists as Novel Inhibitors of Non-Canonical Polyubiquitylation

  2010cited by this paper
• Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence

  2010cited by this paper
• The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis

  2010cited by this paper
• The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.

  2010cited by this paper
• Will the ubiquitin system furnish as many drug targets as protein kinases?

  2010cited by this paper
• Building ubiquitin chains: E2 enzymes at work

  2009cited by this paper
• Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53

  2009cited by this paper
• RING domain E3 ubiquitin ligases.

  2009influential reference
• An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

  2009influential reference
• Physiological functions of the HECT family of ubiquitin ligases

  2009cited by this paper
• EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.

  2008cited by this paper
• Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis.

  2008cited by this paper
• Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer

  2008cited by this paper
• The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

  2008cited by this paper
• Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

  2008cited by this paper
• Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp.

  2008influential reference
• Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1–S transition

  2008cited by this paper
• Dissection of the APCCdh1-Skp2 Cascade in Breast Cancer

  2008cited by this paper
• Association of SAP130/SF3b-3 with Cullin-RING ubiquitin ligase complexes and its regulation by the COP9 signalosome

  2008cited by this paper

• FTO O-GlcNAcylation promotes TRIM21-mediated FTO ubiquitination degradation to sustain the negative feedback control of macrophage inflammation

  2025cites this paper
• VAPA suppresses BEFV and VSV-induced type I IFNs signaling response by targeting JAK1 for NEDD4-mediated ubiquitin-proteasome degradation.

  2025cites this paper
• Prognostic Value of UBE2S, HIF‐1α, and FOXM1 Expression in Esophageal Squamous Cell Carcinoma

  2025cites this paper
• Nanomaterials exert biological effects by influencing the ubiquitin-proteasome system.

  2024cites this paper
• The Magic and Mystery of TRIM65 in Diseases.

  2024cites this paper
• F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects

  2024cites this paper
• E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation.

  2024cites this paper
• Degradation meets development: Implications in β‐cell development and diabetes

  2024cites this paper
• Role of protein degradation systems in colorectal cancer

  2024cites this paper
• STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease.

  2024cites this paper
• Cross-regulation of Listeria monocytogenes and the host ubiquitin system in listeriosis.

  2024cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024cites this paper
• The role of UBR5 in tumor proliferation and oncotherapy.

  2024cites this paper
• Tumor Necrosis Factor Receptor-Associated Factor 6 and Human Cancer: A Systematic Review of Mechanistic Insights, Functional Roles, and Therapeutic Potential

  2024cites this paper
• Stress and recovery of yellowtail kingfish (Seriola aureovittata) during Sea-land relay transportation: Biochemical, microecological and transcriptomic responses

  2024cites this paper
• UBE3C tunes autophagy via ATG4B ubiquitination

  2023cites this paper
• Predicting anti‑cancer drugs’ dissolution in supercritical carbon dioxide

  2023cites this paper
• Association Between Autophagy and Ubiquitin-proteasome System in Age-related Macular Degeneration

  2023cites this paper
• Research Progress of UBE2S in Digestive Sys-tem Tumors

  2023cites this paper
• Functional Role of RING Ubiquitin E3 Ligase VdBre1 and VdHrd1 in the Pathogenicity and Penetration Structure Formation of Verticillium dahliae

  2023cites this paper
• E3-ubiquitin ligases and recent progress in osteoimmunology

  2023cites this paper
• Roles of USP9X in cellular functions and tumorigenesis (Review)

  2023cites this paper
• The role of ubiquitination in microbial infection induced endothelial dysfunction: potential therapeutic targets for sepsis

  2023cites this paper
• Phosphorylation of RasGRP1 by Shc3 prevents RasGRP1 degradation and contributes to Ras/c-Jun activation in hepatocellular carcinoma

  2023cites this paper
• Significance of Plant E3 ubiquitin ligases in NPK homeostasis: A review

  2023cites this paper
• RNF182 induces p65 ubiquitination to affect PDL1 transcription and suppress immune evasion in lung adenocarcinoma

  2023cites this paper
• UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb

  2023cites this paper
• UBE2C-mediated autophagy inhibition via ubiquitination of SIRT1 contributes to endometrial cancer progression.

  2023cites this paper
• Overexpression of tripartite motif-containing 47 (TRIM47) confers sensitivity to PARP inhibition via ubiquitylation of BRCA1 in triple negative breast cancer cells

  2023cites this paper
• The Role of Ubiquitin-Proteasome System in the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus-2 Disease

  2023cites this paper
• E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination

  2022cites this paper
• Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.

  2022cites this paper
• An F-box protein ACOZ1 functions in crossover formation by ensuring proper chromosome compaction during maize meiosis.

  2022cites this paper
• Ultrasound-targeted microbubble destruction-mediated silencing of FBXO11 suppresses development of pancreatic cancer

  2022cites this paper
• Inhibitors of the ubiquitin proteasome system block myofibril assembly in cardiomyocytes derived from chick embryos and human pluripotent stem cells

  2022cites this paper
• A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective

  2022cites this paper
• A Ubiquitin-Proteasome Gene Signature for Predicting Prognosis in Patients With Lung Adenocarcinoma

  2022cites this paper
• An integrative pan-cancer analysis revealing the difference in small ring finger family of SCF E3 ubiquitin ligases

  2022cites this paper
• FBXW7 Reduces the Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma by Regulating the Ubiquitination and Degradation of ACTL6A

  2022cites this paper
• E3 Ubiquitin Ligases: Potential Therapeutic Targets for Skeletal Pathology and Degeneration

  2022cites this paper
• Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis

  2022cites this paper
• The Characteristics of FBXO7 and Its Role in Human Diseases.

  2022cites this paper
• The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion

  2021cites this paper
• E3 ubiquitin-protein ligase 2 inhibits cell proliferation, migration, and invasion of non-small cell lung cancer through ubiquitination of Notch1.

  2021cites this paper
• Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis.

  2021cites this paper
• Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

  2021cites this paper
• Parkinson's disease

  2021cites this paper
• [Metabolic pathways controlled by E3 ligases: an opportunity for therapeutic targeting].

  2021cites this paper
• E3 Ubiquitin Ligase-Mediated Regulation of Osteoblast Differentiation and Bone Formation

  2021cites this paper
• Implications of FBXW7 in Neurodevelopment and Neurodegeneration: Molecular Mechanisms and Therapeutic Potential

  2021cites this paper
• Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

  2021cites this paper
• Critical role of cysteine-266 of SIE3 in regulating the ubiquitination and degradation of SIP1 transcription factor in Lotus japonicus

  2021cites this paper
• The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy

  2021cites this paper
• The Role of the Host Ubiquitin System in Promoting Replication of Emergent Viruses

  2021cites this paper
• Human TRIM5α: Autophagy Connects Cell-Intrinsic HIV-1 Restriction and Innate Immune Sensor Functioning

  2021cites this paper
• UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development

  2021cites this paper
• E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.

  2021cites this paper
• RING Finger Protein 38 Mediates LIM Domain Binding 1 Degradation and Regulates Cell Growth in Colorectal Cancer

  2020cites this paper
• Mechanism by which TRAF6 Participates in the Immune Regulation of Autoimmune Diseases and Cancer

  2020cites this paper
• Regulation of Epithelial–Mesenchymal Plasticity by the E3 Ubiquitin-Ligases in Cancer

  2020cites this paper
• HPV E7 inhibits cell pyroptosis by promoting TRIM21-mediated degradation and ubiquitination of the IFI16 inflammasome

  2020cites this paper
• USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target

  2020cites this paper
• [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].

  2020cites this paper
• Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer

  2020cites this paper
• OTT_A_234828 371..379

  2020cites this paper
• The Protein–Protein Interaction Network of Litopenaeus vannamei Haemocytes

  2019cites this paper
• Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

  2019influential citation
• UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer

  2019cites this paper
• Inhibition of UBE2N‐dependent CDK6 protein degradation by miR‐934 promotes human bladder cancer cell growth

  2019cites this paper
• Emerging drug development technologies targeting ubiquitination for cancer therapeutics

  2019cites this paper
• Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by Fragment Screening

  2017cites this paper